SCHEMBL5620549

SCHEMBL5620549

Cc1c(Cl)cccc1C(=O)NC1Cc2ccccc2C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 6/20 0.60
TAS1R1 Q7RTX1 6/20 0.60
TAS1R2 Q8TE23 6/20 0.60
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
LMNA P02545 2/20 0.57
P2RX7 Q99572 1/20 0.52
CHRM4 P08173 2/20 0.47
PRMT5 O14744 1/20 0.47
GRM7 Q14831 3/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 1/20 0.44
USP2 O75604 1/20 0.43
MT-CO2 P00403 1/20 0.43
TTR P02766 1/20 0.43
PLA2G1B P04054 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL738587 0.85 P2RX7 (0.71) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL2078274 0.76 LMNA (0.58) TAS1R3TAS1R1TAS1R2NPC1RAB9A
SCHEMBL702935 0.76 TAS1R3 (1.00) TAS1R3TAS1R1TAS1R2LMNAMEN1
SCHEMBL702936 0.76 TAS1R3 (1.00) TAS1R3TAS1R1TAS1R2LMNAMEN1
SCHEMBL1099137 0.75 LMNA (0.57) NPC1RAB9ALMNAGRM7MEN1
SCHEMBL2079156 0.75 RAB9A (0.54) NPC1RAB9ALMNACHRM4GRM7
SCHEMBL2079188 0.74 NPC1 (0.56) NPC1RAB9ALMNACHRM4GRM7
SCHEMBL4750983 0.74 NPC1 (0.56) NPC1RAB9ALMNAGRM7MEN1
SCHEMBL14988991 0.73 NPC1 (0.52) NPC1RAB9ALMNAP2RX7PRMT5
SCHEMBL10126900 0.73 TAS1R3 (0.54) TAS1R3TAS1R1TAS1R2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179839-B2 Acylated indanyl amines and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-02-20 US disclosed
US-20030055093-A1 Acylated indanyl amines and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055093-A1 Acylated indanyl amines and their use as pharmaceuticals EDNRA, VEGFA, EDNRB TAS1R3 2112/4885TAS1R1 1713/4885TAS1R2 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.